Filing Overview
SOPHiA GENETICS SA filed a Form 6-K for March 2022 on March 15, 2022. The filing covers the company’s 2021 reporting materials, including IFRS consolidated financial statements for the year ended December 31, 2021, Swiss statutory financial statements, a CEO shareholder letter, a compensation report, and a related press release.
The company is a Swiss foreign private issuer that files annual reports on Form 20-F. Its principal executive office is in Saint-Sulpice, Switzerland.
Financial Performance and Position
The provided filing text is limited to the Form 6-K cover page and exhibit index. It does not provide clear values for revenue, profit or loss, cash flow, margins, debt, liquidity, cash balances, or other financial metrics.
Changes Versus Prior Period
The filing text does not provide sufficient financial information to assess changes versus the prior comparable period.
Outlook, Risks, and Unusual Items
The filing identifies a March 15, 2022 press release and CEO letter as exhibits, but their substantive contents are not included in the provided text. Guidance, outlook, management commentary, risks, contingencies, and unusual items therefore cannot be determined from this filing excerpt.
Investor Verification Items
- Review Exhibit 99.1 for reported 2021 results, guidance, and management commentary.
- Review Exhibit 99.3 for IFRS revenue, profitability, cash flow, liquidity, debt, and balance-sheet details.
- Compare the 2021 IFRS financial statements with the prior-year figures to identify material changes.
- Review Exhibit 99.2 for the CEO’s discussion of strategy, operating performance, risks, and outlook.
- Review Exhibits 99.4 and 99.5 for compensation disclosures and Swiss statutory financial information.